Navigation Links
Video: 8-Minute Film Documentary Explores Why Humans Age
Date:11/28/2008

SAN DIMAS, Calif., Nov. 28 /PRNewswire/ --Why Humans Age is the title of an 8-minute documentary film narrated by Bill Sardi, co-founder and formulator of Longevinex(R) (long-jev-in-ex), a nutriceutical product designed to promote healthy aging.

To view the Multimedia News Release, go to:

http://www.prnewswire.com/mnr/longevinex/35829/

The film presents the "overmineralization" theory of aging -- that humans begin to age biologically only after full childhood growth is achieved.

While there are many theories of aging (hormonal, free radical, wear and tear), the overmineralization theory is the only explanation for why humans age at three different speeds:

  1. no biological aging during the childhood growth years, characterized by the shuttling of calcium, iron and copper to make new bones, red blood cells and collagen;
  2. accumulation of these minerals once childhood growth has ceased and progressive aging, as evidenced by the buildup of cellular debris called lipofuscin;
  3. a slight decline in the rate of aging in late life, which has been correlated with reaching a steady state of minerals. For example, iron stores do not increase any further.

The film explains why women live, on average, about 5 to 8 years longer than males. Women do not begin to accumulate minerals until they have reached menopause. During their fertile years, losses of iron and copper during menstruation, and donation of calcium to offspring, explains why women avoid the "rusting and calcification" seen in full-grown males.

The film explains why males at age 40 have double the amount of iron and four times as much calcium in their bodies compared to an equally aged female, and experience double the rate of diabetes, cancer and heart disease.

The film demonstrates how natural mineral chelating (key-lay-ting) molecules, such as those provided in Longevinex(R), can reduce overmineralization and turn back the clock hands of biological time.

The film depicts a first-of-its-kind experiment where measurement of lipofuscin was performed by direct photography of the retina at the back of the eyes of an 80-year old man, and then Longevinex(R) was employed for 5 months, and was found to reduce cellular debris (lipofuscin). This intervention correlated with improvement in five measurable parameters of vision (visual acuity, night, color, contrast and side vision).

The film suggests a day when retinal photographs will measure lipofuscin levels to determine the biological age of an individual, and natural mineral-chelating molecules will be employed to turn back biological time. The removal of lipofuscin would remove any theoretical limits on the maximum achievable lifespan of humans.

The film was produced by Michael Gonzales and Associates and is available for viewing at www.longevinex.com.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.


'/>"/>
SOURCE Longevinex(R)
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Video: Insulet Unveils Video Contest for OmniPod Users
2. Video: OneTouch(R) Teams With Online Diabetes Community to Launch Global Diabetes Handprint Project
3. Video: Boston Scientific Announces FDA Approval of Second-Generation TAXUS(R) Liberte(R) Drug-Eluting Stent
4. Video: Women Unsatisfied With Body and Breasts, Less Likely to Comply With Screenings, Including Mammography
5. Video: Moms Raise Red Flag About the Dangers of Widely Undiagnosed Bleeding Disorder
6. Video: Fortune 1000 Executives: New President Must Fix Education Gap
7. Video: Keppra XR(TM) Approved in the U.S.
8. Video: New Survey Shows Three in Four School Nurses Have Students at Risk for Severe Allergic Reactions Who Do Not Bring Auto-Injectable Epinephrine to School
9. Video: ASMANEX(R) TWISTHALER(R) 110 MCG (Mometasone Furoate Inhalation Powder) is Now Available Nationwide for the Maintenance Treatment of Asthma in Children Ages 4 to 11
10. Video: CSL Behring Provides $1.2M Grant for Worlds First Study of Postpartum Women with VWD, Common Bleeding Disorder
11. Video: New, Advanced Therapy Program Helps People Who Stutter Acquire Fluent Speech
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , March 24, 2017 On ... trading session at 5,817.69, down 0.07%; the Dow Jones ... and the S&P 500 closed at 2,345.96, marginally dropping ... sectors closed in green, 4 sectors finished in red, ... Friday, Stock-Callers.com has initiated reports coverage on the following ...
(Date:3/23/2017)... ... March 23, 2017 , ... Lajollacooks4u is proud to announce it has become the premiere team-building ... challenges for companies around the world, such as Illumina, HP and Qualcomm, and is ranked ... its increasing popularity is due to its new team building format, a way for teams ...
(Date:3/23/2017)...  GlobeImmune, Inc. today announced it has entered into ... shares of its common stock to NantCell, Inc., a ... the sale of its common stock, NantCell has agreed ... GlobeImmune 200,000 shares, an estimated $2.0 million in value, ... pleased to enter into this strategic agreement with NantCell," ...
(Date:3/23/2017)... YORK , March 23, 2017 ... ... of death, putting significant strain on health care systems, in ... cancer diagnoses rises, so too does the development of innovative ... minimum side effects. Among the many types of cancer treatments, ...
Breaking Biology Technology:
(Date:2/14/2017)... , Feb. 14, 2017  Wake Forest Baptist ... as its new chief executive officer (CEO). Freischlag joins ... John D. McConnell , M.D., who last year ... at the Medical Center, after leading it since 2008. ... full scope of Wake Forest Baptist,s academic health system, ...
(Date:2/10/2017)... , Feb 10, 2017 ... new report "Personalized Medicine - Scientific and Commercial Aspects" ... ... personalized medicine. Diagnosis is integrated with therapy for selection of ... on early detection and prevention of disease in modern medicine. ...
(Date:2/8/2017)... 7, 2017  Aware, Inc. (NASDAQ: AWRE ), ... financial results for its quarter and year ended December 31, ... 2016 was $3.9 million compared to $6.9 million in the ... of 2016 was $0.6 million compared to $2.6 million in ... quarter of 2016 was $0.5 million, or $0.02 per diluted ...
Breaking Biology News(10 mins):